iCAD Details Benefits of Xoft Radiation System to Treat Early Breast Cancer at ASTRO Meeting

iCAD Details Benefits of Xoft Radiation System to Treat Early Breast Cancer at ASTRO Meeting
iCAD is releasing new clinical data on an approach known as intraoperative radiation therapy (IORT), using the company’s Xoft Axxent Electronic Brachytherapy (eBx) System, to treat patients with early stage breast cancer and nonmelanoma skin cancer. The data is being presented at the American Society for Radiation Oncology (ASTRO) meeting, now taking place in Boston. iCAD is also showcasing its newest electronic brachytherapy technology at its booth (#4087) at the meeting, which runs through Wednesday, Sept. 28. Brachytherapy is an advanced cancer treatment that relies on the placement of radioactive seeds or sources near a tumor site, giving a high radiation dose to the tumor while reducing exposure to healthy tissues. In the Xoft system,  a miniaturized high dose rate X-ray source is used to apply radiation directly to the cancerous tumor bed. Unlike traditional high-dose rate brachytherapy technologies, this form of brachytherapy does not require radioactive isotopes, heavy shielding, or major capital equipment, so as to reduce treatment costs, improve convenience, and have fewer side effects. "The Xoft System offers our customers the versatility to treat multiple cancer types in one integrated system. Our advanced platform technology streamlines the delivery of care, increasing patient satisfaction and positioning the facility as a leader in patient-centric, value-based medicine," said Ken Ferry,
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.